

Benedetta Terziroli Beretta-Piccoli
Epatocentro Ticino
CH-6900 Lugano
Switzerland

CURRICULUM VITAE AND BIBLIOGRAPHY

1. PERSONAL INFORMATION

Last name: Terziroli Beretta-Piccoli
First name: Benedetta
Birthday: September 20, 1975, Lugano (Switzerland)
Citizenship: Swiss
Marital status: Married - 6 children
Business address: Epatocentro Ticino SA
Via Soldino 5
CH - 6900 Lugano
Switzerland
Private address: Via del Tiglio 29
CH-6900 Lugano
Switzerland
Office phone number +41-91-960 05 03
Office FAX number +41-91-960 87 18
E-mail: benedetta.terziroli@hin.ch
Languages: Italian, German, English, French

2. QUALIFICATIONS

- 2000: Diploma of physician (Swiss Confederation), Award for the best graduation
- 2000: M.D. Thesis (University of Bern, Switzerland)
- 2007: Certification as Internal Medicine Specialist

3. POSTGRADUATE EDUCATION

• INTERNSHIP - RESIDENCY

- 2001-2002: Departement of Internal medicine, Ospedale La Carità, Locarno, Switzerland
- 2003: Department of Neurology, Ospedale Civico, Lugano, Switzerland

- 2004: Division of Infectious diseases, Ospedale Civico, Lugano, Switzerland
- 2005: Division of Palliative care, Ospedale Regionale di Bellinzona, Switzerland
- 2006: Department of Internal Medicine, Ospedale Regionale Lugano, Switzerland

- **CONSULTANT AND PROFESSIONAL POSITIONS**

- 2008-2013: Consultant, Ambulatorio Epatologia, Clinica Luganese, Lugano, Switzerland
- since 2013: Consultant, Epatocentro Ticino, Lugano, Switzerland AND Consultant physician in hepatology Ospedale La Carità, Locarno, Switzerland

4. RESEARCH

- TRAINING - FELLOWSHIP

- 2006-2008: Hospice Ticino
 - since 2013 Epatocentro Ticino, Lugano, Switzerland, Local Principal Investigator for:
 - Identification of common and uncommon gene variations in Primary Biliary Cirrhosis - genPBC study
 - A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (Native)
 - A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (Regenerate)
 - A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis
 - A two-part randomized, double-blind, placebo-controlled multicentre dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy
 - A phase II, multicentre, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
- Investigator initiated trials (Main Investigator):

- Swiss Association for the Study of the Liver study 36: The health burden of primary biliary cholangitis in Switzerland
- Swiss Association for the Study of the Liver study 38: Swiss registry on autoimmune hepatitis
- Swiss Association for the Study of the Liver study 39: Swiss registry on primary biliary cholangitis

5. GRANTS

- Grant for Swiss Primary Biliary Cholangitis, Intercept (CHF 50'166)
- Grant for the Swiss Primary Biliary Cholangitis Registry, Intercept (CHF 165'900)
- Grant for the Swiss Autoimmune Hepatitis Registry, Vifor (CHF 20'000)

6. SOCIETY MEMBERSHIP

- Swiss Medical Association (FMH)
- European Association for the Study of the Liver, EASL
- American Association for the Study of the Liver, AASLD
- Swiss Association for the Study of the Liver, SASL
- Swiss Society for Allergology and Immunology, SSAI
- International Autoimmune Hepatitis Group, IAIHG
- International Primary Sclerosing Cholangitis Study Group, IPSCSG

6. TEACHING ACTIVITY – MASTER'S THESIS AND MEDICAL DOCTORAL THESIS SUPERVISION

7. UNDERGRADUATE MEDICAL STUDENT

8. POSTGRADUATE MEDICAL STUDENT

- CONTINUAL MEDICAL EDUCATION: Responsible for the postgraduate educational program at Epatocentro Ticino

- Scientific meeting organization:

- Simposio Ticinese di Epatologia 2013-2014-2015-2016-2017
- 1st Swiss Autoimmune Liver Diseases Meeting, Lugano, May 20, 2016
- 2nd Swiss Autoimmune Liver Diseases Meeting, Lugano, April 20, 2018
- Ian Mackay Meeting, Lugano, September 23-25.2018.

8. ACTIVITY AS REVIEWER

European Journal of Paediatrics

Journal of Autoimmunity

BMJ open

European Journal of Gastroenterology & Hepatology

9. EDITORIAL BOARDS

- Clinical Reviews in Allergy and Immunology: guest editor, two issues 2017
- Journal of Autoimmunity: guest editor, special issue 2018

10. BIBLIOGRAPHY (EXCLUSIVELY PEER-REVIEWED JOURNALS WITH IMPACT FACTOR)

• Original papers (including systematic reviews)

1. Stoffel PB, Sauvain MJ, von Vigier RO, **Beretta-Piccoli BC**, Ramelli GP, Bianchetti MG: Noninfectious causes of uveitis in 70 Swiss children. Acta Paediatr 2000; 89: 955-958. [[Impact factor 2.04](#); [Maximum ranking 0.64](#)]
2. **Beretta-Piccoli BC**, Sauvain MJ, Gal I, Schibler A, Saurenmann T, Kressebuch H, Bianchetti MG: Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. Eur J Pediatr 2000; 159: 594-601. [[Impact factor 1.92](#); [Maximum ranking 0.57](#)]
3. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, **Terziroli Beretta-Piccoli B**, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007; 12: 931-939. [[Impact factor 2.59](#); [Maximum ranking 0.54](#)]
4. Stickel F, Helbling B, Heim M, Geier A, Hirschi C, **Terziroli Beretta-Piccoli B**, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat 2012;19:77-87. [[Impact factor 4.12](#); [Maximum ranking 0.81](#)]
5. **Terziroli Beretta-Piccoli B**, Guillod C, Marsteller I, Blum R, Mazzucchelli L, Mondino C, Invernizzi P, Gershwin ME, Mainetti C. Primary biliary cholangitis associated with skin disorders: A case

report and review of the literature. Arch Immunol Ther Exp (Warsz) 2017; 65: 299-309. [Impact factor 2.04; Maximum ranking 0.29]

6. Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, **Terziroli Beretta-Piccoli B**, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther 2017; 45: 723-732. [Impact factor 7.29; Maximum ranking 0.96]

7. Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, **Terziroli Beretta-Piccoli B**, Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 2017; 37: 369-376. [Impact factor 4.11; Maximum ranking 0.80]

8. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol 2017;23: 6030-6048. [Impact factor 3.37; Maximum ranking 0.65]

9. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, **Terziroli Beretta-Piccoli B**, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascués C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017; 37: 694-699. [Impact factor 4.11; Maximum ranking 0.80]

10. Fraga M, Doerig C, Moulin H, Bihl F, Brunner F, Müllhaupt B, Ripellino P, Semela D, Stickel F, **Terziroli Beretta-Piccoli B**, Aubert V, Telenti A, Greub G, Sahli R, Moradpour D. Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. Liver Int doi: 10.1111/liv.13557. [Impact factor 4.11; Maximum ranking 0.80]

11. **Terziroli Beretta-Piccoli B**, Invernizzi P, Gershwin ME, Mainetti C. Skin manifestations associated with autoimmune liver diseases: a systematic review. Clin Rev Allergy Immunol 2017; 53: 394-412. [Impact factor 5.26; Maximum ranking 0.885] DOI 10.1007/s12016-017-8649-9

12. Terziroli Beretta-Piccoli B, Stirnimann G, Cerny A, Semela D, Hessler R, Helbling B, Stickel F, Khalid-de Bakker C, Bihl F, Giostra E, Filipowicz Sinnreich M, Oneta C, Baserga A, Invernizzi P, Carbone M, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: lessons from Switzerland. Clin Rev Allergy Immunol 2017. [Impact factor 5.26; Maximum ranking 0.885] DOI 10.1007/s12016-017-8656-x

13. Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, Bruggmann P, **Terziroli B**, Semela D, Brezzi M, Bertisch B, Estill J, Negro F, Spoerri A; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. *J Viral Hepat* 2017. [Impact factor 4.122; Maximum ranking 0.81] DOI: 10.1111/jvh.12803.

14. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Bertoli R, Mazzucchelli L, Nofziger C, Paulmichl M, Vergani D. Atovaquone/proguanil-induced autoimmune-like hepatitis. *Hepatol Comm* 2017 DOI: 10.1002/hep4.1039.

• Narrative reviews

1. Pfefferle M, Bihl F, **Terziroli Beretta-Piccoli B**, Cerny A. Betreuung des Patienten mit Leberzirrhose. *Ther Umsch* 2011; 68: 207-211. [Impact factor 0.18]

2. **Terziroli Beretta-Piccoli B**, Schranz M, De Gottardi A, Cerny A. Update Hepatitis B und C. *Praxis (Bern 1994)* 2015; 104: 1393-1397. [Without Impact factor]

3. **Terziroli Beretta-Piccoli B**, Vergani D, Mieli-Vergani G. Autoimmunhepatitis: das Wichtigste für die Praxis. *Ther Umsch* 2017; 74: 115-121. [Impact factor 0.18]

4. Mainetti C, **Terziroli Beretta-Piccoli B**, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. *Clin Rev Allergy Immunol*: accepted for publication. DOI: 10.1007/s12016-017-8652-1 [Impact factor 5.26; Maximum ranking 0.885]

5. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Serology in autoimmune hepatitis. A clinical-practice approach. *Eur J Intern Med* 2017 doi: 10.1016/j.ejim.2017.10.006. [Impact factor 2.96; Maximum ranking 0.83]

6. Lerch M, Mainetti C, **Terziroli Beretta-Piccoli B**, Harr T. Current perspectives on Stevens-Johnson Syndrome and toxic epidermal necrolysis. *Clin Rev Allergy Immunol* 2017, doi: 10.1007/s12016-017-8654-z. [Impact factor 5.26; Maximum ranking 0.885]

7. **Terziroli Beretta-Piccoli B**, Mainetti C, Peeters MA, Laffitte E. Cutaneous granulomatosis: a comprehensive review. *Clin Rev Allergy Immunol*: accepted for publication. [Impact factor 5.26; Maximum ranking 0.885].

• Case reports

1. Truttmann AC, **Beretta-Piccoli BC**, Carvajal MI, Bianchetti MG. Arterial hypertension with normal urinalysis in Henoch-Schönlein disease: a further case. *Pediatr Nephrol* 1998; 12: 252. [Impact factor 2.52; Maximum ranking 0.80]

2. Von Vigier R, Offermann N, **Beretta-Piccoli BC**, Bianchetti MG: Paucisymptomatic hemolytic uremic syndrome. *Pediatr Nephrol* 2000;14: 436-437. [[Impact factor 2.52; Maximum ranking 0.80](#)]
3. Bianchi M, Fornasari D, Antonini RA, **Beretta-Piccoli BC**, Nava S, Neuenschwander H. The pharmacogenetics of morphin-induced analgesia: a case report. *J Pain Symptom Manage* 2008; 36: e10-e12. [[Impact factor 2.91; Maximum ranking 0.82](#)]

[Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. *SMW* 2017](#)